首次人体生殖系靶向HIV纳米颗粒疫苗诱导广泛且公共靶向的辅助性T细胞反应
IAVI G001 1期临床试验评估 eOD-GT8 60mer 纳米颗粒(AS01B佐剂)免疫后T细胞反应;20或100微克剂量两次接种后,84%和93%的受种者分别产生针对eOD-GT8和LumSyn的CD4 T细胞反应,85%受种者反应针对三个LumSyn表位热点之一;疫苗特异性外周CD4 T细胞诱导与eOD-GT8特异性记忆B细胞扩增相关。
要点
- 20或100微克eOD-GT8 60mer(AS01B佐剂)两次接种后诱导强劲多功能性CD4 T细胞。
- 84%受种者产生eOD-GT8特异性CD4辅助T细胞反应,93%产生LumSyn特异性反应。
- 85%受种者CD4 T细胞反应针对三个LumSyn表位热点之一。
核心结论
- eOD-GT8 60mer初免疫苗在人体中诱导强烈的CD4 T细胞反应,并鉴定出可能改善后续异源加强或其它疫苗免疫反应的免疫优势CD4 T细胞表位。
研究设计与样本
- IAVI G001 1期临床试验,测试eOD-GT8 60mer(AS01B佐剂)20或100微克剂量两次接种后的疫苗特异性T细胞诱导及表位特异性。
主要发现
- 20或100微克剂量两次接种后,针对eOD-GT8和LumSyn的强劲多功能性CD4 T细胞被诱导。
- eOD-GT8和LumSyn抗原特异性CD4辅助T细胞反应分别见于84%和93%的受种者。
- 85%受种者的CD4 T细胞反应针对三个LumSyn表位热点之一。
- 疫苗特异性外周CD4 T细胞的诱导与eOD-GT8特异性记忆B细胞扩增相关。
关键数值与推荐
- 针对eOD-GT8的CD4 T细胞反应见于84%受种者,针对LumSyn见于93%受种者。
- 针对三个LumSyn表位热点之一的CD4 T细胞反应见于85%受种者。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The engineered outer domain germline targeting version 8 (eOD-GT8) 60-mer nanoparticle was designed to prime VRC01-class HIV-specific B cells that would need to be matured, through additional heterologous immunizations, into B cells that are able to produce broadly neutralizing antibodies. CD4 T cell help will be critical for the development of such high-affinity neutralizing antibody responses. Thus, we assessed the induction and epitope specificities of the vaccine-specific T cells from the IAVI G001 phase 1 clinical trial that tested immunization with eOD-GT8 60-mer adjuvanted with AS01B. Robust polyfunctional CD4 T cells specific for eOD-GT8 and the lumazine synthase (LumSyn) component of eOD-GT8 60-mer were induced after two vaccinations with either the 20- or 100-microgram dose. Antigen-specific CD4 T helper responses to eOD-GT8 and LumSyn were observed in 84 and 93% of vaccine recipients, respectively. CD4 helper T cell epitope "hotspots" preferentially targeted across participants were identified within both the eOD-GT8 and LumSyn proteins. CD4 T cell responses specific to one of these three LumSyn epitope hotspots were observed in 85% of vaccine recipients. Last, we found that induction of vaccine-specific peripheral CD4 T cells correlated with expansion of eOD-GT8-specific memory B cells. Our findings demonstrate strong human CD4 T cell responses to an HIV vaccine candidate priming immunogen and identify immunodominant CD4 T cell epitopes that might improve human immune responses either to heterologous boost immunogens after this prime vaccination or to other human vaccine immunogens.
引用
- Cohen KW, De Rosa SC, Fulp WJ, et al. A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses. Sci Transl Med. 2023. PMID: 37224227. doi:10.1126/scitranslmed.adf3309
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。